SOLVE THERAPEUTICS
Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics. The company was founded in 2021 and is headquartered in Belmont, California.
SOLVE THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2021-01-01
Address:
Belmont, California, United States
Country:
United States
Total Employee:
11+
Status:
Active
Contact:
858-357-4137
Total Funding:
63.51 M USD
Similar Organizations
BlossomHill Therapeutics
BlossomHill Therapeutics, Inc. is a biopharmaceutical company focusing on oncology and autoimmune disorders.
D2G Oncology
D2G Oncology is a biotechnology company that specializes in relating drugs to genotypes to transform precision cancer therapeutics.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Silverback Therapeutics
Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Employees Featured
Founder
More informations about "Solve Therapeutics"
Solve Therapeutics, Inc. - LinkedIn
Solve Therapeutics, Inc. | 1,048 followers on LinkedIn. A Biopharmaceutical Company Developing First-In-Class Antibody Drug Conjugate and Bispecific Therapeutics | A Biopharmaceutical Company ...See details»
Solve Therapeutics - Crunchbase Company Profile
Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics.See details»
Solve Therapeutics Announces Mission to Advance Novel …
Dec 14, 2022 /PRNewswire/ -- Solve Therapeutics, Inc. (SolveTx), an oncology-focused biopharmaceutical company, announced today its mission to develop novel antibody-based...See details»
Solve Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Aug 14, 2025 Explore Solve Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 6 news, and 1 literature, Disease Domain:Neoplasms ...See details»
Solve Therapeutics - PitchBook
Information on valuation, funding, cap tables, investors, and executives for Solve Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Solve Therapeutics, Inc. Company Overview, Contact Details ...
Jan 21, 2022 Innovative Therapeutics Solve Therapeutics focuses on developing first-in-class antibody drug conjugates and bispecific therapeutics, positioning it as an emerging player with …See details»
Solve Therapeutics - Products, Competitors, Financials, Employees ...
Oct 24, 2024 About Solve Therapeutics SolveTX offers a biotechnology platform focused on researching biopharmaceutical medicines. It develops first-in-class antibody-drug conjugates …See details»
Solve Therapeutics | Pharmaceutical | The Pharmaletter …
Jun 3, 2024 Solve Therapeutics An oncology-focused biopharmaceutical company dedicated to developing novel antibody-based therapies targeting tumor-specific antigens. Since its founding in late 2021, Solve has been …See details»
Solve Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Solve Therapeutics, Inc. of San Diego, CA. Get the latest business insights from Dun & Bradstreet.See details»
Solve Therapeutics | General Atlantic
Solve Therapeutics is a biopharmaceutical company that develops next-gen antibody-drug conjugates and bispecific therapeutics for cancer.See details»
Solve Therapeutics, Inc. - North Carolina Life Sciences Organization
Organization Overview Solve is an early-stage biotechnology company focusing on research and development of various cancer therapies.See details»
Solve Therapeutics Announces Mission to Advance Novel
Dec 14, 2022 Solve Therapeutics, Inc. (SolveTx), an oncology-focused biopharmaceutical company, announced today its mission to develop novel antibody-based therapies targeting …See details»
Solve Therapeutics Announces Mission to Advance Novel Antibody
Dec 15, 2022 Solve Therapeutics, announced its mission to develop novel antibody-based therapies targeting tumor-specific antigens.See details»
About Solve Therapeutics | Solve Therapeutics, Inc. - LinkedIn
About Solve Therapeutics Solve Therapeutics is a San Diego-based, venture-backed biotechnology company founded in 2021 and led by industry veterans with a track record of …See details»
Solve Therapeutics - M&A Summary and Business Overview - Mergr
Solve Therapeutics is a biopharmaceutical company developing novel antibody-based therapeutics. Solve Therapeutics was founded in 2021 and is based in San Diego, California.See details»
Solve Therapeutics - News & Analysis - Crunchbase
Dec 23, 2024 Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics.See details»
Solve Therapeutics Announces Mission to Advance Novel …
SAN DIEGO, Dec. 14, 2022 /PRNewswire/ -- Solve Therapeutics, Inc. (SolveTx), an oncology-focused biopharmaceutical company, announced today its mission to develop novel antibody …See details»
Solve Therapeutics launches to tackle cancer - Labiotech.eu
Dec 15, 2022 Solve Therapeutics, an oncology-focused biopharma company, has launched with the mission of developing novel antibody-based therapies.See details»
Series A - Solve Therapeutics - 2022-01-21 - Crunchbase
Jan 21, 2022 Overview Organization Name Solve Therapeutics Announced Date Jan 21, 2022 Funding Type Series A Funding Stage Early Stage Venture Money Raised obfuscatedSee details»
Solve Therapeutics Announces Mission to Advance Novel …
The foundation of SolveTx’s approach to oncology therapeutics development is the identification of novel cancer-specific targets and the generation of mAbs with ideal characteristics to serve …See details»